Mark Knudson - ReShape Lifesciences CoFounder CEO

ReShape Lifesciences Management Efficiency

The company has return on total asset (ROA) of (0.6346) % which means that it has lost $0.6346 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8459) %, meaning that it created substantial loss on money invested by shareholders. ReShape Lifesciences' management efficiency ratios could be used to measure how well ReShape Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.12 in 2024. Return On Capital Employed is likely to drop to -2.23 in 2024. At this time, ReShape Lifesciences' Total Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 4 M in 2024, whereas Other Assets are likely to drop slightly above 111.4 K in 2024.

Similar Executives

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. ReShape Lifesciences (RSLS) is traded on NASDAQ Exchange in USA. It is located in 18 Technology Drive, Irvine, CA, United States, 92618 and employs 29 people. ReShape Lifesciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

ReShape Lifesciences Leadership Team

ReShape Stock Performance Indicators

Additional Tools for ReShape Stock Analysis